Meta-Analysis Suggests Low Risk of Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease Receiving a Gadolinium-Based Contrast Agent
11 Dec, 2019 | 08:23h | UTCRisk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis – JAMA Internal Medicine (free for a limited period)
Invited Commentary: Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease—Is Zero Good Enough? – JAMA Internal Medicine (free for a limited period)